

Italo Poggesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8655262/publications.pdf>

Version: 2024-02-01

56
papers

1,831
citations

331670

21
h-index

276875

41
g-index

57
all docs

57
docs citations

57
times ranked

2461
citing authors

#	ARTICLE	IF	CITATIONS
1	Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 297-310.	4.7	63
2	Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 119-128.	2.4	9
3	Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. <i>Xenobiotica</i> , 2021, 51, 177-193.	1.1	8
4	Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1239-1250.	3.5	5
5	An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1227-1237.	3.5	5
6	A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1605-1619.	3.5	2
7	Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1365-1390.	5.0	7
8	Prediction of the drug-drug interaction potential of the ± 1 acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1107-1118.	2.5	6
9	A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1345-1352.	3.3	3
10	Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 101-111.	1.6	11
11	Population pharmacokinetics of trabectedin in adolescent patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 707-717.	2.3	2
12	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	7.0	181
13	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. <i>Pharmaceutical Research</i> , 2019, 36, 93.	3.5	4
14	Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 668-676.	2.0	4
15	Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs. <i>Clinical Pharmacokinetics</i> , 2018, 57, 505-514.	3.5	3
16	Mathematical modeling of efficacy and safety for anticancer drugs clinical development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 5-21.	5.0	7
17	Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. <i>Investigational New Drugs</i> , 2018, 36, 476-486.	2.6	5
18	Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Pharmacokinetics</i> , 2017, 56, 55-63.	3.5	16

#	ARTICLE	IF	CITATIONS
19	Current mathematical models for cancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-15.	5.0	15
20	Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. <i>Blood</i> , 2016, 128, 4403-4403.	1.4	0
21	Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 111-121.	2.3	58
22	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3170-3177.	7.0	57
23	Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 611-626.	1.8	1
24	Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.. <i>Clinical Cancer Research</i> , 2015, 21, B19-B19.	7.0	3
25	Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1397-1408.	3.3	15
26	Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1149-1160.	3.5	43
27	Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET. <i>Journal of Psychopharmacology</i> , 2014, 28, 244-253.	4.0	19
28	The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 631-635.	3.3	19
29	Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1147-1157.	2.3	30
30	Modeling of human tumor xenografts and dose rationale in oncology. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e365-e372.	4.0	36
31	Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans. <i>Journal of Psychopharmacology</i> , 2013, 27, 435-443.	4.0	18
32	Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1057-1069.	3.3	45
33	Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches. <i>IEEE Transactions on Biomedical Engineering</i> , 2011, 58, 3156-3164.	4.2	4
34	Re: Antitumor Efficacy Testing in Rodents. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1592-1593.	6.3	8
35	Physiologically based pharmacokinetics (PBPK). <i>Drug Metabolism Reviews</i> , 2009, 41, 391-407.	3.6	108
36	Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 837-856.	5.0	26

#	ARTICLE	IF	CITATIONS
37	Drug metabolism and pharmacokinetics. Drug Metabolism Reviews, 2009, 41, 344-390.	3.6	72
38	From pharmacokinetics to therapeutics. Drug Metabolism Reviews, 2009, 41, 455-474.	3.6	3
39	First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery. Journal of Medicinal Chemistry, 2009, 52, 293-307.	6.4	72
40	Pharmacokinetics in special populations. Drug Metabolism Reviews, 2009, 41, 422-454.	3.6	20
41	A Minimal Model of Tumor Growth Inhibition. IEEE Transactions on Biomedical Engineering, 2008, 55, 2683-2690.	4.2	26
42	Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. European Journal of Pharmaceutical Sciences, 2007, 31, 190-201.	4.0	29
43	Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems. European Journal of Pharmaceutical Sciences, 2007, 32, 169-181.	4.0	5
44	Computational Models for Identifying Potential P-Glycoprotein Substrates and Inhibitors. Molecular Pharmaceutics, 2006, 3, 33-44.	4.6	106
45	A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. British Journal of Clinical Pharmacology, 2005, 59, 355-364.	2.4	37
46	A Pharmacokinetic-Pharmacodynamic Model for Predicting Tumour Growth Inhibition in Mice: A Useful Tool in Oncology Drug Development. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 265-268.	2.5	27
47	The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemotherapy and Pharmacology, 2004, 53, 475-481.	2.3	23
48	Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents. Cancer Research, 2004, 64, 1094-1101.	0.9	432
49	Predicting human pharmacokinetics from preclinical data. Current Opinion in Drug Discovery & Development, 2004, 7, 100-111.	1.9	6
50	In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time. Cancer Chemotherapy and Pharmacology, 2003, 52, 507-513.	2.3	9
51	Pharmacokinetics of Single-Dose Reboxetine in Volunteers with Renal Insufficiency. Journal of Clinical Pharmacology, 2000, 40, 482-487.	2.0	25
52	Hemodynamic effects of reboxetine in healthy male volunteers*. Clinical Pharmacology and Therapeutics, 1999, 66, 282-287.	4.7	25
53	Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics., 1999, 20, 53-57.		41
54	A MODEL BASED ASSESSMENT OF REDISTRIBUTION DEPENDENT ELIMINATION AND BIOAVAILABILITY OF RIFABUTIN., 1996, 17, 223-236.		11

#	ARTICLE	IF	CITATIONS
55	Persistence of increased levels of ribosomal gene activity in CHO-K1 cells treated in vitro with demethylating agents. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 348, 187-192.	1.1	4
56	High-performance liquid chromatographic assay of iomeprol in plasma and urine. Biomedical Applications, 1990, 525, 401-409.	1.7	11